Correlation Between KL-6,IL-17 and CTD-ILD
-
摘要:
目的 比较KL-6、IL-17在CTD-ILD与CTD中表达水平的差异,探讨KL-6、IL-17在CTD-ILD中的诊断价值,并分析KL-6、IL-17与肺弥散功能的相关性,为CTD-ILD的诊断和病情严重程度的评估提供依据。 方法 选取2022年9月1日至2024年01月31日就诊于昆明市第一人民医院的患者。总共收集结缔组织病合并间质性肺疾病患者30例,纳为实验组,即CTD-ILD组;总共收集结缔组织病患者39例,纳为对照组,即CTD组。采用ELISA双夹心抗体法检测KL-6、IL-17,将收集数据进行相关性分析。 结果 (1)CTD-ILD组的血清KL-6、IL-17高于CTD组,差异有统计学意义(P < 0.05)。(2)KL-6与DLCO%pred之间存在负相关关系(P < 0.05),IL-17与DLCO%pred不存在相关关系。(3)通过绘制受试者工作特性曲线(ROC)显示:KL-6、IL-17对诊断CTD-ILD 的AUC分别为0.902、0.656。 结论 KL-6、IL-17可作为诊断CTD-ILD的指标,其中,KL-6的诊断价值高于IL-17。KL-6可作为评价肺弥散功能严重程度的指标;而IL-17不能作为评价肺弥散功能严重程度的指标。 -
关键词:
- 结缔组织病合并间质性肺疾病 /
- 血清涎液化糖链抗原-6 /
- 白介素-17
Abstract:Objective To compare the expression levels of KL-6 and IL-17 in CTD-ILD and CTD, to explore the diagnostic value of KL-6 and IL-17 in CTD-ILD, and to analyze the correlation between KL-6 and IL-17 and pulmonary diffusion function, provide a basis for the diagnosis and severity assessment of CTD-ILD. Methods Patients who visited Kunming First People's Hospital between September 1, 2022, and January 31, 2024, were selected. A total of 30 patients with connective tissue diseases combined with interstitial lung disease were collected for the experimental group, referred to as the CTD-ILD group. 39 patients with connective tissue diseases were collected for the control group, referred to as the CTD group. The ELISA double-sandwich antibody method was used to detect KL-6 and IL-17, and correlation analysis was performed on the collected data. Results (1) Serum KL-6 and IL-17 levels in the CTD-ILD group were higher than those in the CTD group, and the difference was statistically significant (P < 0.05). (2) There is a negative correlation between KL-6 and DLCO%pred, while there is no correlation between IL-17 and DLCO%pred(P < 0.05). (3) The receiver operating characteristic curve (ROC) analysis showed that the AUC for KL-6 and IL-17 in diagnosing CTD-ILD were 0.902 and 0.656, respectively. Conclusion KL-6 and IL-17 can serve as indicators for diagnosing CTD-ILD, with KL-6 having a higher diagnostic value than IL-17. KL-6 can be used to assess the severity of lung diffusion function, while IL-17 is not suitable for evaluating the severity of lung diffusion function. -
表 1 CTD-ILD组和CTD组一般资料对比[$ \bar x \pm s $/M(P25-P75)]
Table 1. Comparison of general information between the two groups [$\bar x \pm s $/M(P25-P75)]
参数 CTD-ILD组 CTD组 统计量(t/χ2) P 例数(n) 30 39 − − 年龄(岁) 65.17 ± 10.15 62.85 ± 12.61 0.823 0.413 性别 男[n(%)] 16(53.33) 15(38.46) 1.516 0.218 女[n(%)] 14(46.67) 24(61.54) 表 2 CTD-ILD组、CTD组KL-6、IL-17资料对比[M(P25-P75)]
Table 2. Comparison of KL-6 and IL-17 data between the two groups[M(P25-P75)]
参数 CTD-ILD CTD 统计量(Z) P KL-6(U/L) 620.56(496.36,861.98) 255.00(153.23,371.17) −6.456 <0.001* IL-17(pg/mL) 8.56(6.71,11.33) 6.96(4.48,10.15) −2.504 0.012* *P < 0.05。 表 3 KL-6、IL-17与DLCO%pred的相关性分析
Table 3. Correlation analysis of KL-6,IL-17 and DLCO%pred
参数 DLCO%pred Spearman系数 P KL-6 −0.794 < 0.001* IL-17 −0.165 0.087 *P < 0.05。 表 4 KL-6、IL-17在CTD-ILD中的诊断价值
Table 4. Diagnostic value of KL-6 and IL-17 in CTD-ILD
参数 AUC Cut-off 灵敏度
(%)特异度
(%)95%CI 上限 下限 KL-6(U/L) 0.902 405.44 90 82.1 0.830 0.974 IL-17(pg/mL) 0.656 6.56 86.7 46.7 0.548 0.764 -
[1] 中华医学会呼吸病学分会,中国医师协会呼吸医师分会. 间质性肺疾病多学科讨论规范中国专家共识[J]. 中华结核和呼吸杂志,2023,46(12):1176-1188. [2] Podolanczuk A J,Wong A W,Saito S,et al. Update in Interstitial Lung Disease 2020[J]. American Journal of Respiratory and Critical Care Medicine,2021,203(11):1343-1352. doi: 10.1164/rccm.202103-0559UP [3] Shao T,Shi X,Yang S,et al. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations [J]. Frontiers in Immunology,2021,12:684699. [4] 邹庆华,路跃武,周京国,等. 结缔组织病相关间质性肺疾病诊疗规范[J]. 中华内科杂志,2022,61(11):1217-1223. doi: 10.3760/cma.j.cn112138-20220525-00406 [5] Wijsenbeek M,Suzuki A,Maher T M. Interstitial lung diseases[J]. Lancet (London,England),2022,400(10354):769-786. doi: 10.1016/S0140-6736(22)01052-2 [6] Li L,Zuo X,Luo H,et al. Mortality trend of inpatients with connective tissue diseases: 2005-2014[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban = Journal of Central South University Medical sciences,2017,42(8):927-933. [7] 张慧琴,刘学军. IL-17和IL-6在大鼠肺纤维化过程中的动态表达及意义[J]. 中国医药导报,2012,9(10):24-25+8. doi: 10.3969/j.issn.1673-7210.2012.10.013 [8] 张静静,李青,王丹阳,等. 血清KL-6水平检测在临床间质性肺病诊断中的研究进展[J]. 现代检验医学杂志,2022,37(04):198-204. doi: 10.3969/j.issn.1671-7414.2022.04.039 [9] 杨红娇. IL-27、KL-6在诊断CTD-ILD中的价值 [D]. 昆明:昆明医科大学,2019. [10] Cerro Chiang G,Parimon T. Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): Genetics,cellular pathophysiology,and biologic drivers [J]. International Journal of Molecular Sciences,2023,24(3): 2405. [11] Kohno N,Akiyama M,Kyoizumi S,et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies,KL-3 and KL-6,against lung adenocarcinoma[J]. Japanese Journal of Clinical Oncology,1988,18(3):203-216. [12] 朱雪华,秦亦如,农骐郢,等. 血清涎液化糖链抗原6对肺部疾病预警作用研究进展[J]. 中国职业医学,2023,50(01):104-109. [13] Inoue Y,Kaner R J,Guiot J,et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype[J]. Chest,2020,158(2):646-659. doi: 10.1016/j.chest.2020.03.037 [14] Aloisio E,Braga F,Puricelli C,et al. Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Clinical Chemistry and Laboratory Medicine,2021,59(8):1400-1408. doi: 10.1515/cclm-2021-0199 [15] Fathi M,Barbasso Helmers S,Lundberg I E. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis[J]. Journal of Internal Medicine,2012,271(6):589-597. doi: 10.1111/j.1365-2796.2011.02459.x [16] Salazar G A,Kuwana M,Wu M,et al. KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease[J]. The Journal of Rheumatology,2018,45(8):1153-1158. doi: 10.3899/jrheum.170518 [17] Kim H C,Choi K H,Jacob J,et al. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease[J]. PloS One,2020,15(3):e0229997. doi: 10.1371/journal.pone.0229997 [18] 赵静,王静,李鸿斌. 血清涎液化糖链抗原-6水平与类风湿关节炎伴间质性肺疾病患者免疫功能的相关性研究[J]. 中华风湿病学杂志,2021,25(10):676-679. doi: 10.3760/cma.j.cn141217-20210429-00165 [19] 马芹,徐建华,王芬,等. 结缔组织病间质性肺病血清涎液化糖链抗原-6肺泡表面活性蛋白A和D及白细胞介素-6的变化及意义[J]. 中华风湿病学杂志,2017,21(1):46-49. doi: 10.3760/cma.j.issn.1007-7480.2017.01.010 [20] 刘玉梦,许爱国,赵玉苗,等. 血清KL-6对多发性肌炎/皮肌炎合并肺部疾病的临床价值[J]. 中国实用医刊,2017,44(10):10-12. doi: 10.3760/cma.j.issn.1674-4756.2017.10.004 [21] 吴雪,武丽君,罗采南,等. 涎液化糖链抗原-6在结缔组织病相关间质性肺病诊断中的应用价值[J]. 中华医学杂志,2019,99(40):3172-3175. doi: 10.3760/cma.j.issn.0376-2491.2019.40.010 [22] 杨红娇,董昭兴,王颖,等. IL-27、KL-6在诊断CTD-ILD中的价值[J]. 国际呼吸杂志,2020,40(12):911-916. doi: 10.3760/cma.j.cn131368-20190613-00869 [23] Wakamatsu K,Nagata N,Kumazoe H,et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis[J]. Respiratory Investigation,2017,55(1):16-23. doi: 10.1016/j.resinv.2016.09.003 [24] Kawaguchi M,Adachi M,Oda N,et al. IL-17 cytokine family [J]. The Journal of Allergy and Clinical Immunology,2004,114(6): 1265-1273. [25] Tezcan D,Sivrikaya A,Ergün D,et al. Evaluation of serum interleukin-6 (IL-6),IL-13,and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients[J]. Clinical Rheumatology,2021,40(11):4713-4724. doi: 10.1007/s10067-021-05773-w [26] Tan H L,Rosenthal M. IL-17 in lung disease: friend or foe?[J]. Thorax,2013,68(8):788-790. doi: 10.1136/thoraxjnl-2013-203307 [27] 张瑾,宋宁,高耐芬,等. IL-17和IL-6在特发性肺纤维化患者中的表达及意义[J]. 临床肺科杂志,2016,21(02):210-212+6. doi: 10.3969/j.issn.1009-6663.2016.02.006 [28] 高耐芬,郭洁,张瑾,等. 特发性肺纤维化患者免疫球蛋白A、TGF-β1、IL-6和IL-17水平变化的意义[J]. 河北医药,2019,41(06):881-883+7. [29] Zhang J,Wang D,Wang L,et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease[J]. American Journal of Physiology Lung Cellular and Molecular Physiology,2019,316(3):L487-497. doi: 10.1152/ajplung.00301.2018